1. Photothermal nanofibres enable safe engineering of therapeutic cells, allowing for the intracellular delivery of biologics with high efficiency and throughput.
2. The photothermal nanofibres have been used to deliver effector molecules, including CRISPR–Cas9 ribonucleoprotein complexes and short interfering RNA, to adherent and suspension cells without affecting cell proliferation or phenotype.
3. In vivo experiments demonstrated successful tumour regression in mice treated with chimeric antibody receptor T cells after nanofibre photoporation with short interfering RNA to PD1.
The article is generally reliable and trustworthy as it provides evidence for its claims through experiments conducted on both adherent and suspension cells, as well as in vivo experiments on mice. The authors also provide a comprehensive list of references which further supports the validity of their findings. Furthermore, the article does not appear to be biased or one-sided, as it presents both sides of the argument equally and acknowledges potential risks associated with the use of photothermal nanofibres for therapeutic applications. However, there are some points that could be explored further such as the potential long-term effects of using photothermal nanofibres for therapeutic applications, which are not discussed in detail in this article. Additionally, there is no mention of any ethical considerations related to using these nanofibres for therapeutic purposes, which should be addressed in future research.